Independent
Tenure on this board
9.5 yrs
Also a director at
Duke Energy Corp (DUK)
Meeting calendar
ILMN · Annual meeting · Thursday, May 21, 2026
Illumina Inc
9 nominees · 3 ballot items.
Election of nine directors; ratification of Ernst & Young LLP as independent auditor for fiscal 2026; advisory vote to approve named executive officer compensation.
Market cap
$28.2B
1Y TSR
+78.5%
Board grade
C-
Record date
Mar 26, 2026
Filing
DEF 14A
Meeting concluded · May 21, 2026
Follow how the vote landed and what changed on Illumina Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Directors
ManagementBoard: FORElect nine nominees to the Board of Directors to hold office until the 2027 annual meeting.
- 2
Ratification of Ernst & Young LLP as Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending January 3, 2027.
More detail
This management proposal asks stockholders to ratify EY as the company’s independent auditor for fiscal 2026; the Audit Committee oversees auditor selection and annually reviews EY’s independence and performance. Management seeks ratification as a good governance practice though it is not required, noting EY has served since 2000. The Board recommends a FOR vote because they and the Audit Committee concluded EY’s retention is in the best interests of Illumina and its stockholders; the proxy discloses pre-approval policies, auditor fees, and that an EY representative will attend the meeting to answer questions.
- 3
Advisory Vote to Approve Named Executive Officer Compensation (Say-on-Pay
ManagementBoard: FORNon-binding, advisory vote to approve the compensation of the named executive officers as disclosed in the proxy statement.
More detail
This management proposal seeks an advisory approval of executive pay as disclosed in the CD&A and related tables. Management requests a FOR vote to affirm their compensation program which emphasizes pay-for-performance, significant at-risk compensation, PSUs tied to rTSR and operating margin, and other governance features like clawbacks and stock ownership guidelines. The Compensation Committee uses stockholder feedback in designing pay and concluded the program aligns pay with performance; the vote is non-binding but will inform future decisions. The company indicates prior strong stockholder support and that they hold say-on-pay votes annually. The proposal includes detailed disclosure of pay components, performance metrics, and outcomes, and the Board recommends FOR.
Director elections
Nominees on the ballot9
Independent
Tenure on this board
6.5 yrs
Also a director at
Pfizer Inc (PFE)Tempus Ai Inc (TEM)Unitedhealth Group Inc (UNH)
Independent
Tenure on this board
0.3 yrs
Also a director at
Privia Health Group Inc (PRVA)
Independent
Tenure on this board
1.3 yrs
Also a director at
Mgm Resorts International (MGM)Genedx Holdings Corp (WGS)Vestis Corp (VSTS)
Independent
Tenure on this board
2.2 yrs
Also a director at
Exelon Corp (EXC)
Independent
Tenure on this board
10.0 yrs
Independent
Tenure on this board
7.5 yrs
Also a director at
Align Technology Inc (ALGN)
Not independent
Tenure on this board
2.8 yrs
Independent
Tenure on this board
3.1 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Capital World Investors | 10.3% | 15,549,960 | $1.9B |
| 2 | BlackRock, Inc. | 6.1% | 9,198,619 | $1.1B |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4.5% | 6,823,654 | $841M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 4.4% | 6,594,836 | $813M |
| 5 | STATE STREET CORP | 4.2% | 6,429,344 | $792M |
| 6 | WCM INVESTMENT MANAGEMENT, LLC | 3.9% | 5,923,173 | $716M |
| 7 | BlackRock, Inc. | 2.9% | 4,358,280 | $537M |
| 8 | AQR CAPITAL MANAGEMENT LLC | 2.6% | 3,883,772 | $479M |
| 9 | Corvex Management LPActivist | 2.5% | 3,829,608 | $472M |
| 10 | Sessa Capital IM, L.P. | 2.2% | 3,275,849 | $404M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Illumina Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Steris PLCSTE
Annual meeting·Jul 31, 2026·$21.3B
Jazz Pharmaceuticals PLCJAZZ
Annual meeting·Jul 23, 2026·$15.5B
Apogee Therapeutics IncAPGE
Special meeting·Aug 11, 2026·$10.1B
Amneal Pharmaceuticals IncAMRX
Special meeting·Jul 31, 2026·$5.7B
Doximity IncDOCS
Annual meeting·Aug 27, 2026·$3.9B
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.6B
Reference
Frequently asked questions
- When is the Illumina Inc 2026 annual meeting?
- Illumina Inc (ILMN) holds its 2026 annual shareholder meeting on Thursday, May 21, 2026.
- What is the record date for the Illumina Inc 2026 meeting?
- The record date for the Illumina Inc 2026 meeting is Thursday, March 26, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Illumina Inc's 2026 meeting?
- The board is presenting 9 director nominees at the Illumina Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Illumina Inc 2026 meeting?
- Shareholders will vote on 3 proposals at the Illumina Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.